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OBJECTIVE: This study aimed to determine the frequency of coinfections in leprosy patients and whether there is a
relationship between the presence of coinfections and the development of leprosy reactional episodes.
METHOD: A cross-sectional study based on an analysis of the medical records of the patients who were treated at
the Leprosy Clinics of the Ribeira˜o Preto Medical School, University of Sa˜o Paulo, was conducted from 2000 to 2010.
Information was recorded regarding the age, sex, clinical status, WHO classification, treatment, presence of
reactions and coinfections. Focal and systemic infections were diagnosed based on the history, physical
examination, and laboratory tests. Multinomial logistic regression was used to evaluate the associations between
the leprosy reactions and the patients’ gender, age, WHO classification and coinfections.
RESULTS: Two hundred twenty-five patients were studied. Most of these patients were males (155/225 = 68.8%) of
an average age of 49.31¡15.92 years, and the most prevalent clinical manifestation was the multibacillary (MB)
form (n = 146), followed by the paucibacillary (PB) form (n = 79). Erythema nodosum leprosum (ENL) was more
prevalent (78/122 = 63.9%) than the reversal reaction (RR) (44/122 = 36.1%), especially in the MB patients (OR 5.07; CI
2.86-8.99; p,0.0001) who exhibited coinfections (OR 2.26; CI 1.56-3.27; p,0.0001). Eighty-eight (88/225 = 39.1%)
patients exhibited coinfections. Oral coinfections were the most prevalent (40/88 = 45.5%), followed by urinary tract
infections (17/88 = 19.3%), sinusopathy (6/88 = 6.8%), hepatitis C (6/88 = 6.8%), and hepatitis B (6/88 = 6.8%).
CONCLUSIONS: Coinfections may be involved in the development and maintenance of leprosy reactions.
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INTRODUCTION
Leprosy reactional episodes (REs) are serious complica-
tions of leprosy because these reactions are most likely the
predominant cause of permanent nerve damage, leading to
disability and deformities (1). There is an urgent need to
understand the pathogenesis of these alterations to deter-
mine which patients may be considered to be at risk. These
episodes represent an exacerbation of the inflammatory
process that can occur before, during and after treatment for
leprosy (2,3). There are two well-recognized types of
reactions: the reversal reaction (RR) and erythema nodosum
leprosum (ENL). RRs may be caused by an increase in the
cell-mediated Th1 response to Mycobacterium leprae. ENL is a
systemic inflammatory process with the clinical manifesta-
tions of an acute inflammatory reaction; this reaction is
characterized by intralesional neutrophilic infiltrations and
a Th2 response (3,4).
Because both types of reactions are accompanied by an
increased release of inflammatory markers (5,6), it is
possible that these episodes might be associated with
infectious processes, such as systemic viral infections,
urinary tract infections or oral infections. These coinfections
can over-stimulate the host immune system through the
release of numerous inflammatory markers, including
cytokines, acute-phase proteins and chemokines (7-9).
The follow-up of leprosy patients is often interrupted by
recurrent leprosy REs that interfere with the course of the
disease; therefore, it is important to evaluate the role of
coexistent factors in each patient that could be related to the
exacerbation of the M. leprae infection. To this end, the
present study aimed to determine the clinicopathological
profiles of leprosy patients based on the occurrence of
leprosy REs and to evaluate whether the presence of these
reactions could be associated with coinfections.
METHODS
Subjects
The present investigation was a cross-sectional study
of leprosy patients’ medical records, conducted at the
University Hospital of the Ribeira˜o Preto Medical School
from 2000 to 2010. All of the patients who were treated at
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the Leprosy Clinics and whose diagnoses were based on the
Ridley and Jopling classification criteria (1966) (10) were
included in the study. The following clinical data were
considered: age at diagnosis, gender, clinical form of
leprosy, World Health Organization (WHO) classification,
REs, multidrug therapy (MDT) and coinfections confirmed
by clinical and laboratory examinations. Subjects were
excluded if they had not concluded treatment or if they
were pregnant or breastfeeding. The study was approved by
the Ethics Committee of the University Hospital, Ribeira˜o
Preto Medical School, University of Sa˜o Paulo, Brazil.
Study design
The clinical forms of leprosy were characterized as
indeterminate (I), tuberculoid (TT), borderline tuberculoid
(BT), borderline (BB), borderline lepromatous (BL), and
lepromatous leprosy (LL); the leprosy reactions were
characterized as RRs or ENL. The frequencies of the clinical
forms and REs were correlated with the frequency of
coinfections. The diagnosis of leprosy REs was based on the
presence of erythema and/or the infiltration of the previous
lesions; new erythematous or hypochromic lesions; nerve
thickening; edema of the hands, feet or face and/or diffuse
cutaneous hyperesthesia (for RRs); and the presence of
erythematous nodules, with or without systemic symptoms
such as fever, asthenia, nerve thickening and pain, myalgia
and lymphadenitis (for ENL).
Statistical analysis
The odds ratio obtained by multinomial logistic regres-
sion was used to evaluate the associations between the
leprosy reactions and the gender, age, WHO classifica-
tion and coinfections. The statistical significance of these
associations was evaluated by the chi-square (x2) test. The
level of significance was set at 5% in all of the analyses,
which were performed using the Statistical Analysis System
- SASH 9.0 software (San Diego, Cary, NC, USA).
RESULTS
Subjects
The results of the 225 leprosy cases, which were screened
for leprosy reactions and coinfections, are presented in
Tables 1 and 2. Of the 225 patients, 155 (68.8%) were male,
and 70 (31.1%) were female. The mean age of the patients
was 49.31¡15.92 years (range: 4-89). Regarding the clinical
forms, 5.7% (13/225) of the patients exhibited I leprosy,
9.3% (21/225) exhibited TT, 20% (45/225) exhibited BT,
10.6% (24/225) exhibited BB, 20.4% (46/225) exhibited BL,
and 33.7% (76/225) exhibited LL. Regarding the operational
forms, 35.1% (79/225) were PB patients, and 64.9% (146/
225) were MB patients (Table 1).
Reactional episodes
One-hundred twenty-two (122/225 = 54.2%) patients
exhibited REs, 78 (78/122 = 63.9%) presented with ENL,
and 44 (44/122 = 36.1%) exhibited RRs. One-hundred three
(103/225 = 45.8%) patients did not exhibit any REs (Table 2).
ENL was more prevalent in the MB patients (74/78 = 94.9%)
(OR 5.07; CI 2.86-8.99; p,0.0001) and in those patients who
exhibited coinfections (47/88 = 53.4%) (OR 2.26; CI 1.56-3.27;
p,0.0001). The analysis of the RE evolution based on the
MDT revealed that most of the patients with REs (69/
122 = 51.6%) presented these reactions during their MDTs
(Table 1).
Coinfections
Eighty-eight patients (88/225 = 39.1%) exhibited coinfec-
tions, whereas 137 (137/225 = 60.9%) were free of coinfections
(Table 2). The most prevalent coinfections were chronic oral
infections (40/88 = 45.5%), followed by urinary tract infec-
tions (UTIs) (17/88 = 19.3%), sinusopathy (6/88 = 6.8%),
hepatitis C (6/88 = 6.8%), hepatitis B (6/88 = 6.8%), and
intestinal parasitosis (5/88 = 5.7%). The other infections (8/
88 = 9.1%) included pneumonia, oropharyngeal infections,
syphilis, leishmaniasis, tuberculosis, and staphylococcus
infections.
DISCUSSION
The determination of which patients may be considered
to be at risk of developing leprosy REs has important
implications for reducing the morbidity of these inflamma-
tory reactions (11-15). The analysis of our results revealed
that 122 (54.2%) patients presented with REs (Table 1), and
most of the cases (98/122 = 80.3%) were associated with MB
patients rather than PB patients (24/122 = 19.7%). Although
these data are consistent with those from other studies
Table 1 - The number (n) and row percentages (%) of the
demographic and clinical data from the leprosy patients
managed at the Leprosy Clinics of the Ribeira˜o Preto
Clinical Hospital at the Medical School of Sa˜o Paulo
University, calendar period 2000-2010.
Variables Patients
n %
Gender
Male 155 68.9
Female 70 31.1
Age (years)
#30 27 12.0
31-45 62 27.5
46-60 79 35.1
.60 57 25.3
WHO classification
PB 79 35.1
MB 146 64.9
Leprosy evolution
,6 months 71 31.5
6–12 months 65 28.8
.12 months 89 39.5
Leprosy treatment - MDT
6 months 35 15.5
12 months 115 51.1
.12 months 65 28.8
Reactional episodes
Erythema nodosum 78 34.6
Reverse reaction 44 19.6
No reaction 103 45.7
Reactional episodes evolution*
Before MDT 49 40.1
During MDT 63 51.6
After MDT 49 40.1
Coinfections
Yes 88 39.1
No 137 60.9
MDT: multidrug therapy; *Thirty-nine patients presented more than one
reactional episode: 1 before and after MDT, 1 before and during MDT, 35
during and after MDT, and 2 before, during and after MDT.
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(12-14), the results are not typical of a non-endemic region,
such as the area of this present investigation. However,
these findings can be explained by the fact that the present
study was conducted at a referral center that treats patients
with more severe complications, such as leprosy reactions.
Of the two main types of leprosy reactions, ENL is the
most common, with a prevalence of approximately 50%
among leprosy patients (12,14). Most people with ENL have
acute multiple episodes of ENL or chronic ENL over several
years. ENL is recurrent, especially in MB patients. These
episodes involve a type 2 immune-mediated reaction that is
characterized by a peripheral inflammatory reaction (6), and
the disease may manifest as fever, arthralgias, myalgias, an
orexia, and sparse, tender, and erythematous nodules on the
extensor surfaces of the extremities. Conjunctivitis, neuritis,
synovitis, nephritis, hepatosplenomegaly, orchitis, and
lymphadenopathy may also occur (16). Our results demon-
strated that 63.9% (78/122) of the patients with RE had ENL
(Tables 2 and 3). In addition, a high prevalence of ENL was
associated with the MB patients; ENL occurred in 74 (74/
78 = 94.9%) MB patients as opposed to 4 (4/78 = 5.1%) PB
patients. Subjects exhibiting REs were treated with steroids
or immunosuppressive drugs and corticosteroids, and those
patients who presented with multiple recurrent episodes
were excluded from the study.
The analysis of the RE evolution with respect to MDT
revealed that most of the patients with REs (69/122 = 51.6%)
exhibited these reactions during their MDTs (Table 1). The
MDT consists of dapsone, rifampicin and clofazimine; based
on the bacteriostatic effect of dapsone on M. leprae, this
therapy would be expected to promote moderate bacillary
destruction and, consequently, a decreased inflammatory
reaction. However, MDT drugs have different mechanisms
of action, and the bactericidal drug rifampicin (600 mg/
month) promotes massive bacillary destruction and the
release of many antigenic fractions that cause an inflamma-
tory reaction. This reaction, in most cases, is not controlled
by clofazimine (300 mg/month) or by a daily dose of
dapsone (100 mg) and clofazimine (50 mg). These facts
could explain the high proportion of reactions during MDT
in the present study.
The results of the multinomial analysis, after adjusting
for the gender and age group, revealed that the opera-
tional classification and the presence of coinfections were
Table 2 - A comparison of the number (n) and percentages (%) of reactional episodes (RE) by gender, age and the
presence of infections among the leprosy patients managed at the Leprosy Clinics of the Ribeira˜o Preto Clinical Hospital
in the Medical School of Sa˜o Paulo University, calendar period 2000-2010.
Variables
Reversal reaction
(n = 44)
Erythema nodosum
(n=78)
None reaction
(n= 103) p-value*
Gender
Male 28 (63.6) 56 (71.8) 71 (68.9) 0.64
Female 16 (36.4) 22 (28.2) 32 (31.1)
Age (years)
#30 7 (15.9) 7 (9) 13 (12.6) 0.20
31-45 9 (20.4) 28 (36) 25 (24.2)
46-60 12 (27.3) 26 (33.3) 41 (39.8)
.60 16 (36.4) 17 (21.7) 24 (23.4)
WHO classification
PB 20 (45.4) 4 (5.2) 55 (53.4) ,0.0001
MB 24 (54.5) 74 (94.8) 48 (46.6)
Coinfections
Yes 15 (34.1) 47 (60.3) 26 (25.2) ,0.0001
No 29 (65.9) 31 (39.7) 77 (74.8)
*chi-square test.
Table 3 - Multinomial logistic regression model of the risk factors for reactional episodes (reference = no reaction) by the
gender, age, WHO classification, and presence of coinfections in the leprosy patients managed at the Leprosy Clinics of
the Ribeira˜o Preto Clinical Hospital in the Medical School of Sa˜o Paulo University, calendar period 2000-2010. Odds ratio
(OR), 95% confidence interval (95% CI) and p-value.
Variables Reversal reaction vs. None Erythema nodosum vs. None
OR 95% CI p-value OR 95% CI p-value
Gender
Male vs. Female 0.81 0.55-1.20 0.29 0.80 0.53-1.20 0.29
Age (years)
#30{ 1.0 - - - - -
31-45 0.80 0.41-1.55 0.51 1.61 0.87-2.97 0.13
46-60 0.66 0.36-1.19 0.16 0.89 0.50-1.59 0.70
.60 1.47 0.81-2.66 0.20 0.85 0.45-1.61 0.62
WHO classification
MB vs. PB 1.21 0.83-1.76 0.32 5.07 2.86-8.99 ,0.0001
Coinfections
Yes vs. No 1.26 0.85-1.86 0.25 2.26 1.56-3.27 ,0.0001
{relationship used as reference for comparison between the other variables.
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significantly associated with ENL (OR 2.26; CI 1.56-3.27;
p,0.0001) (Table 3). Bacterial loads, clinical forms, MDTs,
and coinfections have been indicated as inducers or
maintainers of the pathogenesis of these disorders (9,14-
17). Based on the particular underlying immunological
pattern of leprosy, the development and/or maintenance of
these episodes might be associated with an infectious
process. Therefore, leprosy patients would possess immu-
nological characteristics that would impair the clearance of
certain viruses, such as the hepatitis B virus (HBV) and
hepatitis C virus (HCV) (15).
In this study, 50.8% (62/122) of the patients with REs (47
ENL and 15 RR) presented with coinfections. By contrast,
most of the patients (n = 103) who did not exhibit any REs
(77/103 = 74.7%) were free of coinfections (Tables 2 and 3).
A relationship between systemic or focal infections and
leprosy reactions has been reported (9,15,17). Studies have
suggested that viral infections, such as hepatitis B and C,
might be risk factors for developing leprosy reactions (15).
We observed that of the patients presenting with coinfec-
tions, 13.6% (12/88) had viral hepatitis, and 5.6% (5/88) had
REs. The most prevalent coinfections detected in our
patients were chronic oral infections (40/88 = 45.5%), which
were associated with the occurrence of ENL. During a
previous study evaluating the clinical and immunological
associations between oral infections and leprosy reactions,
we observed that the leprosy patients with oral infections
exhibited more leprosy reactions associated with higher C-
reactive protein (CRP), chemokine IP-10, interleukin-1 (IL-1)
and interleukin-6 (IL-6) levels than did the leprosy patients
without oral infections, suggesting that oral infections can
maintain the pro-inflammatory state (9,17). These findings
could be explained by the coexistence of leprosy with other
infections, which can modulate the inflammatory reaction
by increasing the expression of inflammatory markers. Most
likely, these inflammatory products could then spill over
into the peripheral circulation, where they would exacerbate
the insidious and chronic evolution of leprosy and conse-
quently induce, stimulate or maintain the inflammatory
reactions during the disease process (9,15-19).
A limitation of this study was the uncertainty about
whether these coinfections preceded the leprosy reactions.
However, because most of the patients presented with
chronic, asymptomatic oral infections and were not aware of
having these infections, it is likely that these coinfections
preceded the leprosy reactions. Furthermore, the effects of
the acute and chronic viral/bacterial/parasitic/fungal
infections on the leprosy reactions were not separately
evaluated. Nevertheless, we have previously reported that
the presence of chronic oral infections may be involved in
the development and maintenance of leprosy reactional
episodes (9,17). The frequency of ENL in this sample of
leprosy patients was higher in the MB patients than in the
PB patients, especially those patients who exhibited coin-
fections; these findings suggest that MB patients who
present with coinfections might be at a higher risk for
leprosy reactions. Therefore, it is necessary to confirm this
observation by screening leprosy patients for chronic
systemic and local infections because treatment of these
coinfections might improve the care of leprosy patients and
help prevent the disabilities caused by leprosy reactions.
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